View in EDS

Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.

Saved in:
Bibliographic Details
Title: Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
Authors: Welch M; Consano Clinical Research, San Antonio, TX, USA., Forst T; Clinical Research Services, Mannheim, Germany; Johannes Gutenberg University, Mainz, Germany., Jia W; Shanghai Sixth People's Hospital, Shanghai, China., Del Pino PO; Eli Lilly and Company, Indianapolis, IN, USA., Denning M; Eli Lilly and Company, Indianapolis, IN, USA., Wu WS; Eli Lilly and Company, Indianapolis, IN, USA., Li J; Eli Lilly and Company, Indianapolis, IN, USA., Liu R; Eli Lilly and Company, Indianapolis, IN, USA., Eifu M; Eli Lilly and Company, Indianapolis, IN, USA., Chen Y; Eli Lilly and Company, Indianapolis, IN, USA. Electronic address: chen_yanyun@lilly.com.
Corporate Authors: ACHIEVE-2 Trial Investigators
Source: Lancet (London, England) [Lancet] 2026 Jun 08. Date of Electronic Publication: 2026 Jun 08.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42259339
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Welch+M%22">Welch M</searchLink>; Consano Clinical Research, San Antonio, TX, USA.<br /><searchLink fieldCode="AU" term="%22Forst+T%22">Forst T</searchLink>; Clinical Research Services, Mannheim, Germany; Johannes Gutenberg University, Mainz, Germany.<br /><searchLink fieldCode="AU" term="%22Jia+W%22">Jia W</searchLink>; Shanghai Sixth People's Hospital, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Del+Pino+PO%22">Del Pino PO</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Denning+M%22">Denning M</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Wu+WS%22">Wu WS</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Li+J%22">Li J</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Liu+R%22">Liu R</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Eifu+M%22">Eifu M</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Chen+Y%22">Chen Y</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA. Electronic address: chen_yanyun@lilly.com.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22ACHIEVE-2+Trial+Investigators%22">ACHIEVE-2 Trial Investigators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%222985213R%22">Lancet (London, England)</searchLink> [Lancet] 2026 Jun 08. <i>Date of Electronic Publication: </i>2026 Jun 08.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>2985213R <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-547X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201406736%22">01406736 </searchLink><i>NLM ISO Abbreviation: </i>Lancet <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42259339
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(26)00800-7
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Welch M
      – PersonEntity:
          Name:
            NameFull: Forst T
      – PersonEntity:
          Name:
            NameFull: Jia W
      – PersonEntity:
          Name:
            NameFull: Del Pino PO
      – PersonEntity:
          Name:
            NameFull: Denning M
      – PersonEntity:
          Name:
            NameFull: Wu WS
      – PersonEntity:
          Name:
            NameFull: Li J
      – PersonEntity:
          Name:
            NameFull: Liu R
      – PersonEntity:
          Name:
            NameFull: Eifu M
      – PersonEntity:
          Name:
            NameFull: Chen Y
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 08
              M: 06
              Text: 2026 Jun 08
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1474-547X
          Titles:
            – TitleFull: Lancet (London, England)
              Type: main
ResultId 1